What MEDVi advertises for compounded tirzepatide, and what to verify before you enroll. Independent — we are not paid by MEDVi.
| Pricing model | Dose-tiered telehealth, cash-pay |
|---|---|
| Starter price | ~$279 introductory |
| Higher-dose price | ~$399–$499 (rises with dose) |
| Annualized cost (est.) | ~$4,500–$5,500 (typical) |
| Dose-based increase | Yes — dose-tiered |
| Shipping | Verify |
| Labs | Verify |
| Provider visits | Verify |
Yes — dose-tiered. Because the price can rise as you titrate up, the figure that matters for your budget is the maintenance-dose price, not the starter price. See why prices increase by dose.
Works with partner compounding pharmacies; confirm the specific dispensing pharmacy, its 503A/503B status, and CoA availability directly.
Because compounded tirzepatide is not FDA-approved as a finished product, the pharmacy is the key quality signal. See what pharmacy fills compounded tirzepatide and 503A vs 503B.
Telehealth; confirm state availability directly.
Confirm whether shipping is included or billed separately.
Cancellation: Confirm cancellation terms; pricing tiers can change as your dose increases.
Refunds: Confirm refund policy directly.
Pricing and policy details were checked July 2026 against publicly available information. Sources:
Spot an error or out-of-date figure? Submit an update or a correction — we verify before changing pages.
As of July 2026, MEDVi's advertised pricing is ~$279 introductory, with higher-dose pricing: ~$399–$499 (rises with dose). Verify current figures directly; compounded tirzepatide is not FDA-approved.
Dose-based increase: Yes — dose-tiered. Confirm the price at your expected maintenance dose before enrolling.
Works with partner compounding pharmacies; confirm the specific dispensing pharmacy, its 503A/503B status, and CoA availability directly.
Telehealth; confirm state availability directly.